Skip to main content
Top
Published in: Clinical and Translational Oncology 6/2018

Open Access 01-06-2018 | Special Article

Recommendations for the follow-up care of female breast cancer survivors: a guideline of the Spanish Society of Medical Oncology (SEOM), Spanish Society of General Medicine (SEMERGEN), Spanish Society for Family and Community Medicine (SEMFYC), Spanish Society for General and Family Physicians (SEMG), Spanish Society of Obstetrics and Gynecology (SEGO), Spanish Society of Radiation Oncology (SEOR), Spanish Society of Senology and Breast Pathology (SESPM), and Spanish Society of Cardiology (SEC)

Authors: A. Barnadas, M. Algara, O. Cordoba, A. Casas, M. Gonzalez, M. Marzo, A. Montero, M. Muñoz, A. Ruiz, F. Santolaya, T. Fernandez

Published in: Clinical and Translational Oncology | Issue 6/2018

Login to get access

Abstract

The increased incidence and decreased mortality of breast cancer have produced an increased number of breast cancer survivors. The type of sequelae and comorbidities that these patients present call for a collaborative follow-up by hospital-based specialized care and primary care. In this document, we present a guideline drafted and agreed among scientific societies whose members care for breast cancer survivors. The purpose of this guideline is to achieve the shared and coordinated follow-up of these patients by specialized care and primary care professionals. In it, we review the health issues derived from the treatments performed, with recommendations about the therapeutic approach to each of them, as well as a proposal for joint follow-up by primary and specialized care.
Literature
1.
go back to reference Rojas MP, Telaro E, Russo A, Moschetti I, Coe L, Fossati R, et al. Follow up strategies for women treated for early breast cancer. Cochrane Database Sys Rev. 2005;25:CD001768. Rojas MP, Telaro E, Russo A, Moschetti I, Coe L, Fossati R, et al. Follow up strategies for women treated for early breast cancer. Cochrane Database Sys Rev. 2005;25:CD001768.
3.
go back to reference Merck B, Vicente F, Clínico en Cáncer de Mama S. Manual de Práctica Clínica en Senología 2012. 2nd ed. Madrid: Fundación Española de Senología y Patología Mamaria; 2012. pp. 119–20. Merck B, Vicente F, Clínico en Cáncer de Mama S. Manual de Práctica Clínica en Senología 2012. 2nd ed. Madrid: Fundación Española de Senología y Patología Mamaria; 2012. pp. 119–20.
4.
go back to reference Tellez de Peralta FJ. Seguimiento y control del cáncer de mama operado. In: Guías Clínicas de la Asociación Española de Cirujanos, Cirugía de la mama. Madrid: Ediciones Arán; 2006. pp. 326–333. Tellez de Peralta FJ. Seguimiento y control del cáncer de mama operado. In: Guías Clínicas de la Asociación Española de Cirujanos, Cirugía de la mama. Madrid: Ediciones Arán; 2006. pp. 326–333.
5.
go back to reference Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:961–5. doi:10.1200/JCO.2012.45.9859.CrossRefPubMed Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:961–5. doi:10.​1200/​JCO.​2012.​45.​9859.CrossRefPubMed
6.
go back to reference Arbona Rovira A, Martínez Lorenzo M, Fierro Barrabés G, Aguinaga Aizcorreta Ma T. Enfermería Oncológica. Unidad de Mama. Hospital de Día. Investigación Oncológica. Manual de Práctica Clínica en Senología 2012. 2nd ed. Madrid: Fundación Española de Senología y Patología Mamaria; 2012. pp. 120–123. Arbona Rovira A, Martínez Lorenzo M, Fierro Barrabés G, Aguinaga Aizcorreta Ma T. Enfermería Oncológica. Unidad de Mama. Hospital de Día. Investigación Oncológica. Manual de Práctica Clínica en Senología 2012. 2nd ed. Madrid: Fundación Española de Senología y Patología Mamaria; 2012. pp. 120–123.
9.
go back to reference Plan integral de atención a los largos supervivientes de cáncer. Sociedad Española de Oncología. Médica (SEOM). Madrid: Zentrum Verlagsgesellschaft.; 2013, pp 77–82. Plan integral de atención a los largos supervivientes de cáncer. Sociedad Española de Oncología. Médica (SEOM). Madrid: Zentrum Verlagsgesellschaft.; 2013, pp 77–82.
11.
12.
go back to reference Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:1303–10. doi:10.1016/S1470-2045(14)70460-7.CrossRefPubMedPubMedCentral Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:1303–10. doi:10.​1016/​S1470-2045(14)70460-7.CrossRefPubMedPubMedCentral
17.
19.
go back to reference Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK, et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women’s Intervention Nutrition Study. J Natl Cancer Inst. 2006;98:1767–76. doi:10.1093/jnci/djj494.CrossRefPubMed Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK, et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women’s Intervention Nutrition Study. J Natl Cancer Inst. 2006;98:1767–76. doi:10.​1093/​jnci/​djj494.CrossRefPubMed
20.
go back to reference Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23:7820–6. doi:10.1200/JCO.2005.13.300.CrossRefPubMed Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23:7820–6. doi:10.​1200/​JCO.​2005.​13.​300.CrossRefPubMed
23.
go back to reference Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, et al. Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA Cancer J Clin. 2016;66:309–25. doi:10.3322/caac.21341.CrossRefPubMed Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, et al. Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA Cancer J Clin. 2016;66:309–25. doi:10.​3322/​caac.​21341.CrossRefPubMed
24.
go back to reference Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for Cancer Treatments and Cardiovascular Toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2768–801. doi:10.1093/eurheartj/ehw211.CrossRefPubMed Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for Cancer Treatments and Cardiovascular Toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2768–801. doi:10.​1093/​eurheartj/​ehw211.CrossRefPubMed
25.
go back to reference Jagsi R, Griffith KA, Koelling T, Roberts R, Pierce LJ. Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer. Cancer. 2007;109:650–7. doi:10.1002/cncr.22452.CrossRefPubMed Jagsi R, Griffith KA, Koelling T, Roberts R, Pierce LJ. Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer. Cancer. 2007;109:650–7. doi:10.​1002/​cncr.​22452.CrossRefPubMed
26.
27.
28.
go back to reference Deutsch M, Land SR, Begovic M, Wieand HS, Wolmark N, Fisher B. The incidence of lung carcinoma after surgery for breast carcinoma with and without postoperative radiotherapy. Results of National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials B-04 and B-06. Cancer. 2003;98:1362–8. doi:10.1002/cncr.11655.CrossRefPubMed Deutsch M, Land SR, Begovic M, Wieand HS, Wolmark N, Fisher B. The incidence of lung carcinoma after surgery for breast carcinoma with and without postoperative radiotherapy. Results of National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials B-04 and B-06. Cancer. 2003;98:1362–8. doi:10.​1002/​cncr.​11655.CrossRefPubMed
Metadata
Title
Recommendations for the follow-up care of female breast cancer survivors: a guideline of the Spanish Society of Medical Oncology (SEOM), Spanish Society of General Medicine (SEMERGEN), Spanish Society for Family and Community Medicine (SEMFYC), Spanish Society for General and Family Physicians (SEMG), Spanish Society of Obstetrics and Gynecology (SEGO), Spanish Society of Radiation Oncology (SEOR), Spanish Society of Senology and Breast Pathology (SESPM), and Spanish Society of Cardiology (SEC)
Authors
A. Barnadas
M. Algara
O. Cordoba
A. Casas
M. Gonzalez
M. Marzo
A. Montero
M. Muñoz
A. Ruiz
F. Santolaya
T. Fernandez
Publication date
01-06-2018
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 6/2018
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1801-4

Other articles of this Issue 6/2018

Clinical and Translational Oncology 6/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine